These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32951937)

  • 1. Characterization of rVSVΔG-ZEBOV-GP glycoproteins using automated capillary western blotting.
    Minsker K; Rustandi RR; Ha S; Loughney JW
    Vaccine; 2020 Oct; 38(45):7166-7174. PubMed ID: 32951937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP).
    Raabe V; Lai L; Morales J; Xu Y; Rouphael N; Davey RT; Mulligan MJ
    Vaccine; 2023 Feb; 41(8):1513-1523. PubMed ID: 36725433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
    Lee AW; Liu K; Lhomme E; Blie J; McCullough J; Onorato MT; Connor L; Simon JK; Dubey S; VanRheenen S; Deutsch J; Owens A; Morgan A; Welebob C; Hyatt D; Nair S; Hamzé B; Guindo O; Sow SO; Beavogui AH; Leigh B; Samai M; Akoo P; Serry-Bangura A; Fleck S; Secka F; Lowe B; Watson-Jones D; Roy C; Hensley LE; Kieh M; Coller BG;
    Clin Infect Dis; 2024 Apr; 78(4):870-879. PubMed ID: 37967326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.
    Halperin SA; Das R; Onorato MT; Liu K; Martin J; Grant-Klein RJ; Nichols R; Coller BA; Helmond FA; Simon JK;
    J Infect Dis; 2019 Aug; 220(7):1127-1135. PubMed ID: 31505665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
    Simon JK; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BG; Welebob C; Hanson ME; Grais RF
    Vaccine; 2022 Nov; 40(46):6599-6606. PubMed ID: 36208978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon.
    Alabi A; Kokou K; Mahmoudou S; Kavishna R; Nakka SS; Rothenberger S; Musangomunei FP; Olubiyi BF; Bie-Ondo JC; Kabwende AL; Velavan TP; ; Medaglini D; Nakaya HI; Engler O; Harandi AM; Siegrist CA; Kremsner PG; Agnandji ST
    J Infect; 2024 Oct; 89(4):106237. PubMed ID: 39121969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.
    Halperin SA; Arribas JR; Rupp R; Andrews CP; Chu L; Das R; Simon JK; Onorato MT; Liu K; Martin J; Helmond FA;
    J Infect Dis; 2017 Jun; 215(12):1789-1798. PubMed ID: 28549145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.
    Vianello E; Gonzalez-Dias P; van Veen S; Engele CG; Quinten E; Monath TP; Medaglini D; ; ; Santoro F; Huttner A; Dubey S; Eichberg M; Ndungu FM; Kremsner PG; Essone PN; Agnandji ST; Siegrist CA; Nakaya HI; Ottenhoff THM; Haks MC
    Lancet Microbe; 2022 Feb; 3(2):e113-e123. PubMed ID: 35544042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials.
    Grais RF; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BA; Welebob C; Hanson ME; Simon JK
    Lancet Microbe; 2021 Feb; 2(2):e70-e78. PubMed ID: 35544244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlates of vaccine-induced protective immunity against Ebola virus disease.
    Medaglini D; Santoro F; Siegrist CA
    Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.
    ElSherif MS; Brown C; MacKinnon-Cameron D; Li L; Racine T; Alimonti J; Rudge TL; Sabourin C; Silvera P; Hooper JW; Kwilas SA; Kilgore N; Badorrek C; Ramsey WJ; Heppner DG; Kemp T; Monath TP; Nowak T; McNeil SA; Langley JM; Halperin SA;
    CMAJ; 2017 Jun; 189(24):E819-E827. PubMed ID: 28630358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational success of fundamental virology: a VSV-vectored Ebola vaccine.
    Anderson EM; Coller B-AG
    J Virol; 2024 Mar; 98(3):e0162723. PubMed ID: 38305150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.
    Monath TP; Fast PE; Modjarrad K; Clarke DK; Martin BK; Fusco J; Nichols R; Heppner DG; Simon JK; Dubey S; Troth SP; Wolf J; Singh V; Coller BA; Robertson JS;
    Vaccine X; 2019 Apr; 1():100009. PubMed ID: 31384731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline Asymptomatic Malaria Infection and Immunogenicity of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein.
    Mahon BE; Simon J; Widdowson MA; Samai M; Rogier E; Legardy-Williams J; Liu K; Schiffer J; Lange J; DeByle C; Pinner R; Schuchat A; Slutsker L; Goldstein S
    J Infect Dis; 2021 Dec; 224(11):1907-1915. PubMed ID: 34013349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knowledge, attitudes, and practices and long-term immune response after rVSVΔG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda.
    Waltenburg MA; Kainulainen MH; Whitesell A; Nyakarahuka L; Baluku J; Kyondo J; Twongyeirwe S; Harmon J; Mulei S; Tumusiime A; Bergeron E; Haberling DL; Klena JD; Spiropoulou C; Montgomery JM; Lutwama JJ; Makumbi I; Driwale A; Muruta A; Balinandi S; Shoemaker T; Cossaboom CM
    Vaccine; 2024 Sep; 42(22):126031. PubMed ID: 38880693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Gamma Irradiation on the Antibody Response Measured in Human Serum from Subjects Vaccinated with Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine.
    Grant-Klein RJ; Antonello J; Nichols R; Dubey S; Simon J
    Am J Trop Med Hyg; 2019 Jul; 101(1):207-213. PubMed ID: 31162004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease.
    Tell JG; Coller BG; Dubey SA; Jenal U; Lapps W; Wang L; Wolf J
    Vaccines (Basel); 2020 Dec; 8(4):. PubMed ID: 33352786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
    Huttner A; Agnandji ST; Engler O; Hooper JW; Kwilas S; Ricks K; Clements TL; Jonsdottir HR; Nakka SS; Rothenberger S; Kremsner P; Züst R; Medaglini D; Ottenhoff T; Harandi AM; Siegrist CA; ; ;
    Clin Microbiol Infect; 2023 Dec; 29(12):1587-1594. PubMed ID: 37661067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
    Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I
    Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.
    Boum Y; Juan-Giner A; Hitchings M; Soumah A; Strecker T; Sadjo M; Cuthbertson H; Hayes P; Tchaton M; Jemmy JP; Clarck C; King D; Faga EM; Becker S; Halis B; Gunnstein N; Carroll M; Røttingen JA; Kondé MK; Doumbia M; Henao-Restrepo AM; Kieny MP; Cisse M; Draguez B; Grais RF
    Vaccine; 2020 Jun; 38(31):4877-4884. PubMed ID: 32499066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.